文献速递心力衰竭与心肌病

沙库巴曲/缬沙坦对比缬沙坦对射血分数保留型心衰前患者左房容积的影响:PARABLE随机临床试验

Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

PARABLE试验在250例射血分数保留型心衰前(pre-HFpEF)患者中比较沙库巴曲/缬沙坦与缬沙坦对左房容积指数的影响。结果显示沙库巴曲/缬沙坦组左房容积指数增加更明显(6.9 mL/m2 vs 0.7 mL/m2,P<.001),但脉压和NT-proBNP改善更优,主要不良心血管事件更少(4.9% vs 13.3%,校正HR 0.38)。

要点

  • 沙库巴曲/缬沙坦较缬沙坦更显著增加左房容积指数(6.9 vs 0.7 mL/m2,P<.001)。
  • 沙库巴曲/缬沙坦组脉压和NT-proBNP降低更明显。
  • 沙库巴曲/缬沙坦组主要不良心血管事件发生率更低(4.9% vs 13.3%)。

核心结论

  • 在pre-HFpEF患者中,沙库巴曲/缬沙坦治疗与左房容积指数增加更明显相关,但心血管风险标志物改善更优。
  • 需进一步研究沙库巴曲/缬沙坦在pre-HFpEF患者中心脏容积增加及长期效应。

研究设计与样本

  • PARABLE为前瞻性、双盲、双模拟随机临床试验,2015年4月至2021年6月于爱尔兰都柏林单中心门诊心内科开展。
  • 共纳入250例无症状、年龄≥40岁、合并高血压或糖尿病、BNP>20 pg/mL或NT-proBNP>100 pg/mL、左房容积指数>28 mL/m2、射血分数>50%的pre-HFpEF患者。
  • 患者随机接受沙库巴曲/缬沙坦滴定至200 mg每日两次或缬沙坦滴定至160 mg每日两次。

主要发现

  • 沙库巴曲/缬沙坦组最大左房容积指数增加6.9 mL/m2(95%CI 0.0-13.7),缬沙坦组增加0.7 mL/m2(95%CI -6.3-7.7),P<.001。
  • 沙库巴曲/缬沙坦组脉压变化为-4.2 mm Hg(95%CI -7.2至-1.21),缬沙坦组为-1.2 mm Hg(95%CI -4.1至1.7),P<.001。
  • 沙库巴曲/缬沙坦组NT-proBNP变化为-17.7%(95%CI -36.9至7.4),缬沙坦组为9.4%(95%CI -15.6至4.9),P<.001。

临床怎么用

  • 对于pre-HFpEF患者,沙库巴曲/缬沙坦可改善脉压和NT-proBNP等心血管风险标志物。
  • 沙库巴曲/缬沙坦可能降低主要不良心血管事件风险,但需权衡左房容积增加的意义。
  • 沙库巴曲/缬沙坦在pre-HFpEF中的应用需进一步研究长期获益与风险。

局限性

  • 研究为单中心设计,结果外推性受限。
  • 样本量250例,事件数较少,主要不良心血管事件分析需谨慎解读。
  • 左房容积指数增加与临床获益的长期关系尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pre-heart failure with preserved ejection fraction (pre-HFpEF) is common and has no specific therapy aside from cardiovascular risk factor management. OBJECTIVE: To investigate the hypothesis that sacubitril/valsartan vs valsartan would reduce left atrial volume index using volumetric cardiac magnetic resonance imaging in patients with pre-HFpEF. DESIGN, SETTING, AND PARTICIPANTS: The Personalized Prospective Comparison of ARNI [angiotensin receptor/neprilysin inhibitor] With ARB [angiotensin-receptor blocker] in Patients With Natriuretic Peptide Elevation (PARABLE) trial was a prospective, double-blind, double-dummy, randomized clinical trial carried out over 18 months between April 2015 and June 2021. The study was conducted at a single outpatient cardiology center in Dublin, Ireland. Of 1460 patients in the STOP-HF program or outpatient cardiology clinics, 461 met initial criteria and were approached for inclusion. Of these, 323 were screened and 250 asymptomatic patients 40 years and older with hypertension or diabetes, elevated B-type natriuretic peptide (BNP) greater than 20 pg/mL or N-terminal pro-b-type natriuretic peptide greater than 100 pg/mL, left atrial volume index greater than 28 mL/m2, and preserved ejection fraction greater than 50% were included. INTERVENTIONS: Patients were randomized to angiotensin receptor neprilysin inhibitor sacubitril/valsartan titrated to 200 mg twice daily or matching angiotensin receptor blocker valsartan titrated to 160 mg twice daily. MAIN OUTCOMES AND MEASURES: Maximal left atrial volume index and left ventricular end diastolic volume index, ambulatory pulse pressure, N-terminal pro-BNP, and adverse cardiovascular events. RESULTS: Among the 250 participants in this study, the median (IQR) age was 72.0 (68.0-77.0) years; 154 participants (61.6%) were men and 96 (38.4%) were women. Most (n = 245 [98.0%]) had hypertension and 60 (24.0%) had type 2 diabetes. Maximal left atrial volume index was increased in patients assigned to receive sacubitril/valsartan (6.9 mL/m2; 95% CI, 0.0 to 13.7) vs valsartan (0.7 mL/m2; 95% CI, -6.3 to 7.7; P < .001) despite reduced markers of filling pressure in both groups. Changes in pulse pressure and N-terminal pro-BNP were lower in the sacubitril/valsartan group (-4.2 mm Hg; 95% CI, -7.2 to -1.21 and -17.7%; 95% CI, -36.9 to 7.4, respectively; P < .001) than the valsartan group (-1.2 mm Hg; 95% CI, -4.1 to 1.7 and 9.4%; 95% CI, -15.6 to 4.9, respectively; P < .001). Major adverse cardiovascular events occurred in 6 patients (4.9%) assigned to sacubitril/valsartan and 17 (13.3%) assigned to receive valsartan (adjusted hazard ratio, 0.38; 95% CI, 0.17 to 0.89; adjusted P = .04). CONCLUSIONS AND RELEVANCE: In this trial of patients with pre-HFpEF, sacubitril/valsartan treatment was associated with a greater increase in left atrial volume index and improved markers of cardiovascular risk compared to valsartan. More work is needed to understand the observed increased cardiac volumes and long-term effects of sacubitril/valsartan in patients with pre-HFpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04687111.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ledwidge, Dodd, Ryan, et al. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 36884247. doi:10.1001/jamacardio.2023.0065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。